BRCA2 and breast cancer: The mechanism explaining how ER signaling can contribute to worsened BC progression in BRCA1/BRCA2 mutation carriers is unknown; however, preclinical data demonstrated estrogen-dependent progression of mammary tumorigenesis in BRCA1-defficient cells [29,30].